AHL
AZN icon

Abel Hall LLC’s AstraZeneca AZN Stock Holding History

Abel Hall LLC’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$570K Sell
3,006
-3,665
-55% -$689K 0.1% 198
2026
Q1 		$1.32M Buy
6,671
+3,462
+108% +$668K 0.28% 46
2025
Q4 		$590K Buy
3,209
+368
+13% +$64.5K 0.14% 132
2025
Q3 		$436K Buy
2,841
+113
+4% +$17.1K 0.18% 111
2025
Q2 		$381K Sell
2,728
-398
-13% -$55.8K 0.18% 118
2025
Q1 		$459K Buy
3,126
+900
+40% +$130K 0.28% 58
2024
Q4 		$292K Sell
2,226
-16
-0.7% -$2.24K 0.19% 92
2024
Q3 		$349K Sell
2,242
-65
-3% -$10.5K 0.23% 77
2024
Q2 		$360K Buy
2,307
+389
+20% +$58.5K 0.25% 65
2024
Q1 		$260K Buy
1,918
+76
+4% +$10.1K 0.19% 94
2023
Q4 		$248K Buy
+1,842
New +$239K 0.21% 86

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Abel Hall LLC's AZN Position: Q2 2026 in Review

Abel Hall LLC reduced its AstraZeneca (AZN) stake by 55% in Q2 2026, selling an estimated $689K and leaving 3,006 shares worth $570K. The position accounts for 0.1% of the portfolio, ranked #198.

Abel Hall LLC first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.32M in Q1 2026. 534 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Abel Hall LLC held 3,006 shares of AstraZeneca worth $570K as of Q2 2026.
  • Abel Hall LLC sold 3,665 AstraZeneca shares in Q2 2026, an estimated $689K.
  • AstraZeneca made up 0.1% of Abel Hall LLC's portfolio in Q2 2026, its #198 holding.
  • Abel Hall LLC first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
  • Abel Hall LLC's AstraZeneca position peaked at $1.32M in Q1 2026.
  • 534 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.